Can cycle day 7 FSH concentration during controlled ovarian stimulation be used to guide FSH dosing for in vitro fertilization?

Reproductive Biology and Endocrinology

Robert F Casper¹  Navid Esfandiari²  Ross Firestone¹  Courtney Firestone¹  Eliezer Burstein¹  Yaakov Bentov¹ 

[1] Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, ON, Canada;Division of Reproductive Sciences, Department of Obstetrics and Gynecology, University of Toronto, Toronto, ON, Canada

关键词: Ovarian stimulation;    In vitro fertilization;    Poor ovarian response;    FSH elimination;    Serum FSH concentration;   

Others  :  812635
DOI  :  10.1186/1477-7827-11-12

 received in 2012-08-24, accepted in 2013-02-12,  发布年份 2013

【 摘 要 】

Background

When stimulating a patient with poor ovarian response for IVF, the maximal dose of gonadotropins injected is often determined by arbitrary standards rather than a measured response. The purpose of this study was to determine if serum FSH concentration during an IVF stimulation cycle reflects follicular utilization of FSH and whether serum FSH values may inform dose adjustments of exogenous FSH.

Methods

In this retrospective cross sectional study we studied 155 consecutive IVF cycles stimulated only with recombinant human FSH. We only included long GnRH agonist protocols in which endogenous FSH levels were suppressed. We correlated the serum concentration of cycle day (CD) 7 FSH with the number of oocytes retrieved, cleaving embryos and pregnancy rate.

Results

We found that a CD7 FSH concentration above 22 IU/L was associated with poor response regardless of the daily dose of FSH injected and a lower pregnancy rate.

Conclusions

We concluded that CD7 FSH concentration during stimulation could be used to guide FSH dosing in poor responders. If the CD7 FSH concentration is above 22 IU/L increasing the dose of FSH in an attempt to recruit more growing follicles is unlikely to be successful.

【 授权许可】

   
2013 Bentov et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Bodri D, Sunkara SK, Coomarasamy A: Gonadotropin-releasing hormone agonists versus antagonists for controlled ovarian hyperstimulation in oocyte donors: a systematic review and meta-analysis. Fertil Steril 2011, 95:164-169.
• [2]Feigenberg T, Simon A, Ben-Meir A, Gielchinsky Y, Laufer N: Role of androgens in the treatment of patients with low ovarian response. Reprod Biomed Online 2009, 19:888-898.
• [3]Smulders B, van Oirschot SM, Farquhar C, Rombauts L, Kremer JA: Oral contraceptive pill, progestogen or estrogen pre-treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques. Cochrane Database Syst Rev 2010, 1:CD006109. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=20091585 webcite
• [4]Shoham Z, Mannaerts B, Insler V, Coelingh-Bennink H: Induction of follicular growth using recombinant human follicle-stimulating hormone in two volunteer women with hypogonadotropic hypogonadism. Fertil Steril 1993, 59:738-742.
• [5]Mannaerts BM, Rombout F, Out HJ, Coelingh Bennink H: Clinical profiling of recombinant follicle stimulating hormone (rFSH; Puregon): relationship between serum FSH and efficacy. Hum Reprod Update 1996, 2:153-161.
• [6]Ferraretti AP, La Marca A, Fauser BC, Tarlatzis B, Nargund G, Gianaroli L: ESHRE consensus on the definition of ‘poor response’ to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod 2011, 26:1616-1624.
• [7]Mannaerts B, Fauser B, Lahlou N, Harlin J, Shoham Z, Bennink HC, Bouchard P: Serum hormone concentrations during treatment with multiple rising doses of recombinant follicle stimulating hormone (Puregon) in men with hypogonadotropic hypogonadism. Fertil Steril 1996, 65:406-410.
• [8]Selman H, Pacchiarotti A, El-Danasouri I: Ovarian stimulation protocols based on follicle-stimulating hormone glycosylation pattern: impact on oocyte quality and clinical outcome. Fertil Steril 2011, 94:1782-1786.
• [9]Fletcher PW, Reichert LE Jr: Cellular processing of follicle-stimulating hormone by Sertoli cells in serum-free culture. Mol Cell Endocrinol 1984, 34:39-49.
• [10]Katz P, Showstack J, Smith JF, Nachtigall RD, Millstein SG, Wing H, Eisenberg ML, Pasch LA, Croughan MS, Adler N: Costs of infertility treatment: results from an 18-month prospective cohort study. Fertil Steril 2011, 95:915-921.
• [11]Gonzalez-Comadran M, Duran M, Sola I, Fabregues F, Carreras R, Checa MA: Effects of transdermal testosterone in poor responders undergoing IVF: systematic review and meta-analysis. Reprod Biomed Online 2012, 25:450-459.
• [12]Gomaa H, Casper RF, Esfandiari N, Chang P, Bentov Y: Addition of low dose hCG to rFSh benefits older women during ovarian stimulation for IVF. Reprod Biol Endocrinol 2012, 10:55. BioMed Central Full Text